Avistone Wins China Approval For First C-Met Inhibitor In Glioblastoma

 
• By Dexter Jie Yan
  
glioblastoma
Avistone's vebreltinib found effective for rare subtype of glioblastoma in China Phase II/III trial • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from China

More from Focus On Asia